Abstract:The third SARS-CoV-2 pandemic wave causing Omicron variant has comparatively higher replication rate and transmissibility than the second wave-causing Delta variant. The exact mechanism behind the differential properties of Delta and Omicron in respect to infectivity and virulence is not properly understood yet. This study reports the analysis of different mutations within the receptor binding domain (RBD) of spike glycoprotein and non-structural protein (nsp) of Delta and Omicron strains. We have used computa… Show more
“…in July 2023 to Omicron E.G.5.1 in December 2023, with the epidemiology differing by geographical location (Figure 1). The current dominant variants have an immune evasion advantage, but result in less severe infections in the general population [38,47]. Here, more observation is needed to determine how variant transmission impacts the IEI community in terms of infection rates and severity of illness.…”
Section: Sars-cov-2 Variantsmentioning
confidence: 99%
“…For example, the Omicron BA.1 variant, which emerged in November 2021, has 37 spike protein mutations, resulting in increased ACE2 binding affinity and decreased humoral immune recognition [ 45 ]. To date, the Omicron lineage is the most divergent variant due to the high number of mutations it harbors, with all sublineages maintaining properties of increased immune evasion and preference for binding to ACE2 compared to earlier SARS-CoV-2 variants [ 46 , 47 ] ( Table S1 ).…”
The SARS-CoV-2 pandemic has heightened concerns about immunological protection, especially for individuals with inborn errors of immunity (IEI). While COVID-19 vaccines elicit strong immune responses in healthy individuals, their effectiveness in IEI patients remains unclear, particularly against new viral variants and vaccine formulations. This uncertainty has led to anxiety, prolonged self-isolation, and repeated vaccinations with uncertain benefits among IEI patients. Despite some level of immune response from vaccination, the definition of protective immunity in IEI individuals is still unknown. Given their susceptibility to severe COVID-19, strategies such as immunoglobulin replacement therapy (IgRT) and monoclonal antibodies have been employed to provide passive immunity, and protection against both current and emerging variants. This review examines the efficacy of COVID-19 vaccines and antibody-based therapies in IEI patients, their capacity to recognize viral variants, and the necessary advances required for the ongoing protection of people with IEIs.
“…in July 2023 to Omicron E.G.5.1 in December 2023, with the epidemiology differing by geographical location (Figure 1). The current dominant variants have an immune evasion advantage, but result in less severe infections in the general population [38,47]. Here, more observation is needed to determine how variant transmission impacts the IEI community in terms of infection rates and severity of illness.…”
Section: Sars-cov-2 Variantsmentioning
confidence: 99%
“…For example, the Omicron BA.1 variant, which emerged in November 2021, has 37 spike protein mutations, resulting in increased ACE2 binding affinity and decreased humoral immune recognition [ 45 ]. To date, the Omicron lineage is the most divergent variant due to the high number of mutations it harbors, with all sublineages maintaining properties of increased immune evasion and preference for binding to ACE2 compared to earlier SARS-CoV-2 variants [ 46 , 47 ] ( Table S1 ).…”
The SARS-CoV-2 pandemic has heightened concerns about immunological protection, especially for individuals with inborn errors of immunity (IEI). While COVID-19 vaccines elicit strong immune responses in healthy individuals, their effectiveness in IEI patients remains unclear, particularly against new viral variants and vaccine formulations. This uncertainty has led to anxiety, prolonged self-isolation, and repeated vaccinations with uncertain benefits among IEI patients. Despite some level of immune response from vaccination, the definition of protective immunity in IEI individuals is still unknown. Given their susceptibility to severe COVID-19, strategies such as immunoglobulin replacement therapy (IgRT) and monoclonal antibodies have been employed to provide passive immunity, and protection against both current and emerging variants. This review examines the efficacy of COVID-19 vaccines and antibody-based therapies in IEI patients, their capacity to recognize viral variants, and the necessary advances required for the ongoing protection of people with IEIs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.